quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:00:00·1753d
PRRelease
Auris Medical Holding Ltd. logo

Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology

EARS· Auris Medical Holding Ltd.
Health Care
Original source

Companies

  • EARS
    Auris Medical Holding Ltd.
    Health Care

Related

  • SEC1689d
    SEC Form 6-K filed by Auris Medical Holding Ltd.
  • SEC1735d
    SEC Form 6-K filed by Auris Medical Holding Ltd.
  • PR1745d
    Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2
  • PR1761d
    Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany
  • PR1768d
    Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine Model of Adult T-Cell Leukemia / Lymphoma
  • SEC1773d
    SEC Form 6-K filed by Auris Medical Holding Ltd.
  • SEC1781d
    SEC Form EFFECT filed by Auris Medical Holding Ltd.
  • SEC1786d
    SEC Form 6-K filed by Auris Medical Holding Ltd.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022